The L-shaped association between superoxide dismutase levels and blood pressure in older Chinese adults: community-based, cross-sectional study

Ying HUANG*, Wei LAI*, Hong CHEN, Qi-Fan LIU, Ju-Xiang LI✉, Jin-Zhu HU✉
Department of Cardiovascular Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang of Jiangxi, China
*The authors contributed equally to this manuscript
✉Correspondence to: jx912@126.com; hujinzhu1983@sina.com
https://doi.org/10.11909/j.issn.1671-5411.2022.01.002

ABSTRACT

BACKGROUND As an antioxidant, serum superoxide dismutase (SOD) have been found to be associated with hypertension.

METHODS The data were derived from the Chinese Longitudinal Healthy Longevity Survey (CLHLS), a prospective cohort study in China. We explored the association between serum SOD and blood pressure (BP) using multivariable correction analysis in an older Chinese population.

RESULTS We observed a significantly gradual downward trend in the association between serum SOD levels and diastolic BP (DBP) in participants with lower serum SOD levels (< 58 IU/mL), while no associations were observed between serum SOD levels and DBP in participants with higher serum SOD levels (> 58 IU/mL). Similar results showed a significant gradual downward trend in associations between serum SOD levels and the risk of diastolic hypertension only at SOD < 58 IU/mL. Multiple linear regression analysis suggested that serum SOD was negatively correlated with DBP ($S_\beta = —0.088, P < 0.001$) but not with SBP ($S_\beta = 0.013, P = 0.607$). Multiple logistic regression analysis suggested that serum SOD was independently associated with the risk of diastolic hypertension ($OR = 0.984, 95\% CI: 0.973–0.996, P = 0.010$) but not with the risk of systolic hypertension ($OR = 1.001, 95\% CI: 0.990–1.012, P = 0.836$) after adjusting for relevant confounding factors. Serum SOD levels (< 58 IU/mL, > 58 IU/mL) were an effect modifier of the association between serum SOD and DBP ($interaction P = 0.003$) or the risk of diastolic hypertension ($interaction P = 0.005$).

CONCLUSIONS Our study indicated for the first time that there was an L-shaped association between serum SOD levels and the risk of diastolic hypertension in the older Chinese population.

Hypertension is the most important risk factor for death from cardio-cerebral vascular diseases, accounting for 2.54 million deaths among Chinese residents in 2017.[1,2] Although many risk factors for hypertension, including genetics, age, overweight/obesity, high salt intake, smoking, excessive alcohol consumption, insufficient physical activity, chronic mental stress and air pollution, have been identified,[3,4] the incidence rate of hypertension is increasing year by year, suggesting that some potential risk factors are still unknown. Therefore, continuing to find modifiable risk factors or predictors has important clinical value for the early prevention of hypertension.

The role of reactive oxygen species (ROS) in the development of hypertension has been previously investigated. When the vascular structure changes, it can promote the tension of blood vessels to change, affect the development of the whole course of hypertension and lead to irreversible pathological changes.[5] ROS can induce the transition of vascular smooth muscle cells (VSMCs) to a proliferative phenotype, which is characterized by a decrease in the vascular lumen, an increase in medium thickness, an increase in stiffness and a decrease in expandability.[6] ROS also promote inflammatory gene expression and mediate multiple signaling pathways leading to vascular remodeling.[7,8] Cells have
multiple integrated enzymatic and nonenzymatic antioxidant systems to resist oxidative stress. Superoxide dismutase (SOD) was discovered by McCord and Fridovich in 1969 and has a scavenging effect on ROS. Oxidative stress occurs in the kidney and its vascular system during Ang II infusion and high salt intake, which reduces the expression of SOD. SOD plays an important role in endothelial dysfunction in essential hypertension by competing with nitric oxide for superoxide. The pathogenesis of hypertension is related to oxidative stress and endothelial dysfunction, accompanied by changes in serum SOD levels.

Although several previous studies have reported a decreased level and/or low activity of SOD in animal models and/or humans with hypertension, the concrete relationship between SOD level and hypertension is still uncertain. Given the increasing aging of the population and the continuing rise in the prevalence of hypertension, we aimed to investigate whether serum concentrations of SOD contributed to a changed risk of hypertension in a Chinese elderly population.

METHODS

Study Design and Participants

The data for this study were from the Chinese Longitudinal Healthy Longevity Survey (CLHLS), which covers 22 provinces, municipalities and autonomous regions across the country. The subjects were people aged 65 and above. Overall, the national cohort was conducted among an elderly population, with high-quality demographic and socioeconomic characteristics, social and behavioral risk factors, and various biochemical indicators, such as blood and urine tests, for health indicators. The baseline wave was conducted in 1998, followed by follow-up waves in 2000, 2002, 2005, 2008–2009, 2011–2012 and 2014, and a multistage cluster sampling method was used. Details of the study have also been described elsewhere. Participants in the national cohort did not participate in the design of the self-reporting questionnaire in the CLHLS study at the same time. These participants were also not involved in the implementation of our study. All participants or their relatives were informed of the results of systolic BP (SBP) and diastolic BP (DBP) used the data for the CLHLS study.

In this study, we used data from the 2011–2012 wave of the cohort. During the wave, the biomarker sub-study of CLHLS was conducted for various serum indexes including SOD and others. Our study had a sufficient analysis among adults aged 65 and older in the wave with complete information on BP, SOD and other covariates. In total, 1,630 participants were initially included in our study. As shown in Figure 1, we excluded 809 participants due to missing data.

Measurement and Calculation of Blood Pressure

All participants rested for at least 5 min, and trained research assistants used a mercury sphygmomanometer (upper arm type; Yuyue, Jiangsu, China). SBP was measured by Korotkoff phase I and DBP was measured by phase V. The BP of bedridden patients was measured in the recumbent position. The average value of BP was calculated from two measurements for further analysis. The mercury sphygmomanometer must be calibrated before each measurement. For research purposes, DBP ≥ 90 mmHg was defined as diastolic hypertension and SDP ≥ 140 mmHg was defined as systolic hypertension.

Covariates

The covariates were obtained by structured ques-
Sociodemographic characteristics included age, sex, residence and marital status. Other health features included smoking, drinking, activities of daily living, body mass index (BMI), waist circumference, and physician-diagnosed self-reported diseases such as heart disease, stroke, diabetes, and other cardiovascular diseases (CVDs).

Residence is divided into “urban (city or town)” or “rural (rural housing)”. Current smokers and current drinkers were reported by themselves, using “Are you smoking at the moment?” and “are you drinking now?” Current smokers were divided into “current smokers” and “noncurrent smokers”. At present, drinkers were divided into “current drinkers” and “noncurrent drinkers”. Daily life activities can be divided into the following two categories: “regular exercise” and “irregular exercise”. Self-reported diseases can be divided into the following two categories: “yes” and “no”. The waist circumference of lightweight participants were measured with an non-stretchable tape. Measure the distance between the lowest rib and the iliac crest. In the case of our study, if the waist circumference of a participant was at least 80 cm for a woman and at least 85 cm for a man, she or he was defined as overweight. BMI was calculated as weight (kg) divided by height squared (m²). BMI ≥ 25 kg/cm², was defined as overweight.

**Statistical Analysis**

The Kolmogorov-Smirnov test was used to analyze the normality of the data. Non-normally distributed were analyzed by the Mann-Whitney U test and then expressed as the median (interquartile range [IQR]). Normally distributed data were analyzed by the independent t-test and presented as the mean ± SD. The chi-square test was used to analyze categorical variables and is expressed as n (%).

First, we implemented a smooth curve to estimate the relationships of serum SOD levels with SBP and DBP. Second, multiple linear regression analysis was performed to evaluate the associations between serum SOD and SBP and DBP. Third, multiple logistic regression analysis was also performed to evaluate the relationships between SOD and systolic hypertension (SBP ≥ 140 mmHg) and diastolic hypertension (DBP ≥ 90 mmHg). Additionally, we implemented a multiple logistic regression analysis to estimate the relationship between SOD and systolic hypertension (SBP ≥ 140 mmHg) and diastolic hypertension (DBP ≥ 90 mmHg) stratified by sex, overweight, category of residence, CVDs and SOD levels (inflection point = 58 IU/mL). Additionally,
stratified analysis performed by gender, BMI, waist circumference, category of residence, disease history and inflection point of serum SOD. We used four models. Model 1: adjusted for age and gender. Model 2: adjusted for age, sex, current status of smoking, alcohol consumption and exercise. Model 3: adjusted for age, sex, current status of smoking, alcohol consumption, exercise and disease history (diabetes stroke and heart disease). Model 4: adjusted for age, sex, current status of smoking, alcohol consumption, exercise, disease history (diabetes, stroke and heart disease), BMI and blood biomarkers (total cholesterol, low density lipoprotein cholesterol (LDLC), high density lipoprotein cholesterol (HDLC), hypersensitive-c-reactive-protein (hs-CRP), creatine and plasma glucose). All of the analyses were performed using EmpowerStats 3.0. A P value ≤ 0.05 was considered to be statistically significant.

RESULTS

Characteristics of Participants

The present study included 1,630 participants, with an average age of 84, and 839 participants were female (51.5%). The median SBP and DBP were 140.0 mmHg and 80 mmHg, respectively. The median serum SOD levels of the included participants were 57.51 IU/mL in Table 1.

Nonlinear associations were identified between serum SOD and DBP before adjustment for any confounding factors. The smooth curve supported an L-shaped relationship between serum SOD levels and DBP (Figure 2A, P < 0.001) but not with SBP (Figure 2B, P > 0.05). DBP decreased with increasing serum SOD levels up to the turning point (SOD = 58 IU/mL). However, DBP was not correlated with SOD levels when SOD > 58 IU/mL. Similarly, there was an L-shaped relationship between serum SOD levels and the risk of diastolic hypertension (Figure 2C, P < 0.001) but not with the risk of systolic hypertension (Figure 2D, P > 0.05). The risk of diastolic hypertension decreased with increasing serum SOD levels up to the turning point (SOD = 58 IU/mL). Furthermore, all included participants were divided into two groups according to the inflection point of serum SOD levels (58 IU/mL). Compared with participants with low serum SOD levels (serum SOD < 58 IU/mL), high serum SOD levels participants (serum SOD > 58 IU/mL) had significantly lower DBP instead of SBP. We observed a significantly gradual downward trend in associations between serum SOD levels and DBP when SOD < 58 IU/mL, while there were no associations between serum SOD levels and DBP when SOD > 58 IU/mL (Figure 3A). Interestingly, similar results showed a significant gradual downward trend in associations between serum SOD levels and the risk of diastolic hypertension when SOD < 58 IU/mL (Figure 3B).

Association between Serum SOD and BP After Adjusting for Confounding Factors

Multiple linear regression analysis was performed to further prove the association between serum SOD and BP. As shown in Table 2, serum SOD was negatively correlated with DBP (Sβ = −0.088; 95% CI: −0.170 to −0.049; P < 0.001) but not with SBP (Sβ = 0.013; 95% CI: −0.086, 0.147; P = 0.607) in Crude Model. After other confounding factors were added, including age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke and heart disease), BMI and blood biomarkers (total cholesterol, LDLC, HDLC, hs-CRP, creatine and plasma glucose), the serum SOD still had a strong relationship with DBP (Sβ = −0.069; 95% CI: −0.151 to 0.026, P = 0.005, Model 4) but not with SBP (Sβ = 0.014, 95% CI: −0.153 to 0.084, P = 0.564, Model 4). However, there was still no correlation between serum SOD and SBP after these adjustments were made.

Association between Serum SOD and Hypertension After Adjusting for Confounding Factors

Multiple logistic regression analysis was performed to further prove the association between serum SOD and the risk of hypertension. As shown in Table 3, the results suggested that serum SOD was independently associated with the risk of diastolic hypertension (OR = 0.984; 95% CI: 0.973–0.996; P = 0.01; Model 4) after adjustments were made, including for age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke and heart disease), BMI and blood biomarkers (total cholesterol, LDLC, HDLC, hs-CRP, creatine and plasma glucose). Our results
showed that serum SOD was not associated with the risk of systolic hypertension (1.001; 95% CI: 0.990–1.012; \( P = 0.836 \), Model 4) after adjusting for relevant confounding factors.
Multiple linear regression analysis was performed to further prove the association between serum SOD and BP stratified by sex, overweight, category of residence and disease history. As shown in Table 4, we observed no significant effect modifiers between serum SOD and DBP after stratifying the analysis by sex (interaction \( P = 0.5394 \)), BMI (in-
As shown in Table 5, we observed no significant effect modifiers between serum SOD and the risk of diastolic hypertension after the stratified analysis by sex (interaction $P = 0.1327$), BMI (interaction $P = 0.1422$), waist circumference (interaction $P = 0.3095$), category of residence (interaction $P = 0.1282$), heart disease (interaction $P = 0.9642$), stroke (interaction $P = 0.7128$) and diabetes (interaction $P = 0.1621$).

We also observed no significant effect modifiers between serum SOD and BP after the stratified analysis. Multiple logistic regression analysis was performed to further prove the association between serum SOD and hypertension stratified by sex, overweight, category of residence and disease history. As shown in Table 5, we observed no significant effect modifiers between serum SOD and the risk of diastolic hypertension (interaction $P = 0.0050$) but not a modifier of the association between serum SOD and the risk of systolic hypertension (interaction $P = 0.7625$).

**DISCUSSION**

In this prospective cohort including 1630 Chinese adults 65 years or older, our results indicated L-shaped relationships between serum SOD levels and blood pressure.

### Table 2 Multiple linear regression analysis for relationship between SOD and BP.

| Variables | DBP, mmHg | SBP, mmHg |
|-----------|-----------|-----------|
|          | B        | Sβ        | 95% CI       | P-value | B        | Sβ        | 95% CI       | P-value |
| Crude    | −0.109   | −0.088    | −0.170, −0.049 | < 0.001 | 0.030   | 0.013     | −0.086, 0.147 | 0.607   |
| Model 1  | −0.102   | −0.082    | −0.163, −0.041 | 0.001   | −0.041  | −0.017    | −0.156, 0.075 | 0.493   |
| Model 2  | −0.101   | −0.081    | −0.162, −0.040 | 0.001   | −0.040  | −0.017    | −0.155, 0.076 | 0.502   |
| Model 3  | −0.101   | −0.081    | −0.162, −0.040 | 0.001   | −0.036  | −0.015    | −0.152, 0.080 | 0.539   |
| Model 4  | −0.089   | −0.069    | −0.151, −0.026 | 0.005   | −0.034  | −0.014    | −0.153, 0.084 | 0.564   |

Crude: not adjusted; model 1: adjusted for age and gender; model 2: adjusted for age, gender, current status of smoke, alcohol drinking and exercise; model 3: adjusted for age, gender, current status of smoke, alcohol drinking, exercise and disease history (diabetes, stroke and heart disease); model 4: Adjusted for age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke and heart disease), BMI and blood biomarkers (total cholesterol, LDLC, HDLC, hs-CRP, creatine and plasma glucose). BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; HDLC: high-density lipoprotein cholesterol; HR: heart rate; LDLC: low-density lipoprotein cholesterol; SOD: superoxide dismutase.

### Table 3 Multiple Logistic Regression Analysis for Relationship between SOD and High BP (DBP ≥ 90 mmHg or SBP ≥ 140 mmHg).

| Variables | DBP ≥ 90 mmHg | P-value | SBP ≥ 140 mmHg | P-value |
|-----------|---------------|---------|---------------|---------|
|          | OR (95% CI)   |         | OR (95% CI)   |         |
| Crude    | 0.981 (0.970, 0.993) | 0.001   | 0.976 (0.943, 1.010) | 0.354   |
| Model 1  | 0.983 (0.971, 0.994) | 0.003   | 0.999 (0.989, 1.010) | 0.872   |
| Model 2  | 0.983 (0.971, 0.994) | 0.003   | 0.978 (0.944, 1.012) | 0.884   |
| Model 3  | 0.983 (0.971, 0.994) | 0.004   | 1.000 (0.989, 1.010) | 0.936   |
| Model 4  | 0.984 (0.973, 0.996) | 0.010   | 1.001 (0.990, 1.012) | 0.836   |

Crude: not adjusted; model 1: adjusted for age and gender; model 2: adjusted for age, gender, current status of smoke, alcohol drinking and exercise; model 3: adjusted for age, gender, current status of smoke, alcohol drinking, exercise and disease history (diabetes, stroke and heart disease); model 4: Adjusted for age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke and heart disease), BMI and blood biomarkers (total cholesterol, LDLC, HDLC, hs-CRP, creatine and plasma glucose). BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; HDLC: high-density lipoprotein cholesterol; HR: heart rate; LDLC: low-density lipoprotein cholesterol; SOD: superoxide dismutase.

Interaction $P = 0.5192$, waist circumference (interaction $P = 0.7233$), category of residence (interaction $P = 0.9213$), heart disease (interaction $P = 0.4536$), stroke (interaction $P = 0.0741$) and diabetes (interaction $P = 0.6627$). We also observed no significant effect modifiers between serum SOD and SBP after stratification of the analysis. Importantly, serum SOD levels (< 58 IU/mL, > 58 IU/mL) were an effect modifier of the association between serum SOD and DBP (interaction $P = 0.0060$) but not a modifier of the association between serum SOD and SBP (interaction $P = 0.6008$).

**Stratified Analysis for Association between Serum SOD and Risk of Hypertension by Multiple Logistic Regression Analysis**

Multiple logistic regression analysis was performed to further prove the association between serum SOD and hypertension stratified by sex, overweight, category of residence and disease history. As shown in Table 5, we observed no significant effect modifiers between serum SOD and the risk of diastolic hypertension after the stratified analysis by sex (interaction $P = 0.1327$), BMI (interaction $P = 0.1422$), waist circumference (interaction $P = 0.3095$), category of residence (interaction $P = 0.1282$), heart disease (interaction $P = 0.9642$), stroke (interaction $P = 0.7128$) and diabetes (interaction $P = 0.1621$). We also observed no significant effect modifiers between serum SOD and SBP after the stratified analysis. Similarly, serum SOD levels (< 58 IU/mL, > 58 IU/mL) were an effect modifier of the association between serum SOD and the risk of diastolic hypertension (interaction $P = 0.0050$) but not a modifier of the association between serum SOD and the risk of systolic hypertension (interaction $P = 0.7625$).
studies have shown that level and/or activity of \( \text{O}_2^{-} \) into hydrogen peroxide and oxygen. Some catalyzing the dismutation of superoxide anion enzyme that protects against oxidative stress by ant enzyme that protects against oxidative stress by [19].

In recent years, it has been found that oxidative stress plays an important role in the pathogenesis of hypertension by activating the renin-angiotensin-aldosterone system (RAAS). [17,18] SOD is an antioxidant enzyme that protects against oxidative stress by catalyzing the dismutation of superoxide anion \( \text{O}_2^{-} \) into hydrogen peroxide and oxygen. [19] Some studies have shown that level and/or activity of SOD were decreased in animal models and/or humans with hypertension [12,13,19-21]. One study demonstrated that in newly diagnosed hypertensive patients without antihypertensive treatment, SOD levels were lower than those in the normal population, and SOD activity was negatively correlated with both systolic and diastolic blood pressure. [22] SOD3 is closely linked to hypertension among the three SOD isoenzymes because SOD3 plays a key role in regulating \( \text{O}_2^{-} \) levels in the vasculature. Gongora, et al. [20] found that hypertension caused by angiotensin II was greater in Sod3/−/− mice compared with wild-type mice. However, none of these studies clarified the relationship between different serum SOD levels and hypertension.

In the present study, our results indicated that

| Subgroup                                      | DBP, mmHg     | SBP, mmHg     |
|-----------------------------------------------|---------------|---------------|
|                                               | B (95% CI)    | P Interaction | B (95% CI)    | P Interaction |
| Gende                                         |               |               |
| Male                                          | -0.098 (-0.184, -0.012) | 0.026 | 0.5394 | -0.004 (-0.172, 0.163) | 0.958 | 0.3324 |
| Female                                        | -0.105 (-0.198, -0.012) | 0.027 | -0.080 (-0.252, 0.092) | 0.360 |
| BMI, kg/cm²                                    |               |               |
| BMI < 25 (normal)                             | -0.101 (-0.169, -0.033) | 0.004 | 0.5192 | -0.044 (-0.175, 0.087) | 0.507 | 0.8524 |
| BMI ≥ 25 (overweight)                        | -0.034 (-0.193, 0.124) | 0.670 | -0.018 (-0.297, 0.262) | 0.901 |
| Waist circumference, cm                       |               |               |
| Normal male < 90 yrs; female < 85 yrs         | -0.089 (-0.161, -0.017) | 0.015 | 0.7233 | 0.015 (-0.120, 0.150) | 0.823 | 0.3002 |
| Overweight male ≥ 90 yrs; female ≥ 85 yrs     | -0.070 (-0.198, 0.058) | 0.285 | -0.166 (-0.416, 0.083) | 0.191 |
| Category of residence                         |               |               |
| City and town                                 | -0.088 (-0.235, 0.058) | 0.237 | 0.9213 | -0.246 (-0.506, 0.015) | 0.064 | 0.0867 |
| Rural                                         | -0.083 (-0.153, -0.013) | 0.019 | 0.016 (-0.118, 0.149) | 0.815 |
| Suffering from disease (CVDs)                 |               |               |
| Heart disease                                 | -0.067 (-0.304, 0.171) | 0.579 | 0.4536 | -0.034 (-0.446, 0.378) | 0.871 | 0.7638 |
| No heart disease                              | -0.090 (-0.156, 0.025) | 0.007 | -0.022 (-0.146, 0.102) | 0.727 |
| Stroke                                        | -0.295 (-0.534, -0.057) | 0.016 | 0.7401 | 0.015 (-0.396, 0.426) | 0.942 | 0.5760 |
| No stroke                                     | -0.078 (-0.143, -0.014) | 0.017 | 0.032 (-0.093, 0.157) | 0.611 |
| Diabetes                                      | 0.077 (-0.399, 0.533) | 0.742 | 0.6627 | -0.035 (-1.023, 0.954) | 0.943 | 0.4444 |
| No diabetes                                   | -0.097 (-0.159, -0.034) | 0.003 | 0.022 (-0.099, 0.142) | 0.726 |
| SOD < 58 IU/mL                                | -0.205 (-0.327, -0.082) | 0.001 | 0.0038 | 0.005 (-0.222, 0.232) | 0.859 | 0.8060 |
| SOD > 58 IU/mL                                | 0.039 (-0.086, 0.164) | 0.542 | -0.053 (-0.295, 0.190) | 0.750 |

Adjusted for age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke, and heart disease), BMI and blood biomarkers (total cholesterol, LDLC, HDLC, hs-CRP, creatine and plasma glucose). BMI: body mass index; BP: blood pressure; CRP: C-reactive protein; CVDs: cardiovascular diseases; HDLC: high-density lipoprotein cholesterol; HR: heart rate; LDLC: low-density lipoprotein cholesterol; SOD: superoxide dismutase.
serum SOD levels are associated with the risk of diastolic hypertension, and a linear regression model with a smooth curve further showed an L-shaped relationship between serum SOD levels and the risk of diastolic hypertension, while there was no correlation between serum SOD levels and the risk of systolic hypertension. A previous study did not indicate any shaped associations between serum SOD levels and hypertension. Importantly, we found the inflection point for the curve at a serum SOD level of 58 IU/mL, the risk of diastolic hypertension decreased with the increase of serum SOD levels up to the turning point, and the diastolic hypertension was not correlated with SOD levels at SOD > 58 IU/mL. On further analysis, we found that serum SOD levels (< 58 IU/mL, > 58 IU/mL) were an effect modifier of the association between serum SOD and DBP or the risk of diastolic hypertension but not a modifier of the association between serum SOD and SBP or the risk of systolic hypertension. In addition, no significant effect modifiers were found between serum SOD and DBP, SBP, or the risk of diastolic hypertension or systolic hypertension after the stratified analysis by sex, BMI, waist circumference, category of residence, heart disease, stroke and diabetes. According to the results, we can easily judge the risk of diastolic hypertension according to different SOD levels in patients. These findings may provide clinical guidelines on the primary prevention of diastolic hypertension for the Chinese elderly population.

The mechanism driving the link between serum

Table 5  Multiple logistics regression analysis for relationship between SOD and blood pressure stratified by gender, overweight, category of residence and CVD diseases.

| Subgroup                          | DBP ≥ 90 mmHg | SBP ≥ 140 mmHg |
|-----------------------------------|---------------|----------------|
|                                   | OR (95% CI)   | P              | Interaction P | OR (95% CI)   | P              | Interaction P |
| Gender                            |               |                |               |               |                |               |
| Male                              | 0.977 (0.960, 0.994) 0.007 | 0.1327 | 1.008 (0.994, 1.024) 0.264 | 0.1081 |
| Female                            | 0.991 (0.973, 1.009) 0.310 | 0.994 (0.978, 1.010) 0.450 | 0.4460 |
| BMI, kg/cm²                        |               |                |               |               |                |               |
| BMI < 25 (normal)                 | 0.980 (0.967, 0.993) 0.003 | 0.1422 | 1.002 (0.991, 1.014) 0.695 | 0.0695 |
| BMI ≥ 25 (overweight)             | 1.004 (0.975, 1.034) 0.798 | 0.989 (0.961, 1.017) 0.436 | 0.981 (0.958, 1.004) 0.109 |
| Waist circumference, cm           |               |                |               |               |                |               |
| Normal male < 90 yrs; female < 85 yrs | 0.982 (0.968, 0.996) 0.012 | 0.3095 | 1.008 (0.995, 1.020) 0.217 | 0.1940 |
| Overweight male ≥ 90 yrs; female ≥ 85 yrs | 0.996 (0.972, 1.020) 0.720 | 0.981 (0.958, 1.004) 0.109 | 0.987 (0.961, 1.014) 0.342 |
| Category of residence             |               |                |               |               |                |               |
| City and town                     | 1.006 (0.978, 1.035) 0.660 | 0.1282 | 0.987 (0.961, 1.014) 0.342 | 0.1940 |
| Rural                             | 0.980 (0.967, 0.994) 0.005 | 1.005 (0.993, 1.017) 0.448 | 0.1940 |
| Suffering from disease (CVDs)     |               |                |               |               |                |               |
| Heart disease                     | 0.979 (0.941, 1.018) 0.284 | 0.9642 | 0.981 (0.941, 1.022) 0.351 | 0.1589 |
| No heart disease                  | 0.984 (0.972, 0.997) 0.016 | 1.004 (0.992, 1.015) 0.517 | 1.004 (0.992, 1.015) 0.517 |
| Stroke                            | 0.963 (0.922, 1.005) 0.084 | 0.7128 | 1.007 (0.970, 1.046) 0.703 | 0.9855 |
| No stroke                         | 0.985 (0.972, 0.997) 0.016 | 1.006 (0.995, 1.017) 0.311 | 1.006 (0.995, 1.017) 0.311 |
| Diabetes                          | 0.946 (0.832, 1.075) 0.396 | 0.1621 | 0.965 (0.851, 1.093) 0.572 | 0.9429 |
| No diabetes                       | 0.984 (0.972, 0.996) 0.007 | 1.006 (0.995, 1.017) 0.277 | 1.006 (0.995, 1.017) 0.277 |
| SOD                               |               |                |               |               |                |               |
| SOD < 58, IU/mL                   | 0.965 (0.943, 0.988) 0.020 | 0.0050 | 1.000 (0.978, 1.023) 0.988 | 0.7625 |
| SOD > 58 IU/mL                    | 1.012 (0.989, 1.035) 0.322 | 1.006 (0.986, 1.027) 0.628 | 0.7625 |

Adjusted for age, gender, current status of smoke, alcohol drinking, exercise, disease history (diabetes, stroke, and heart disease), BMI and blood biomarkers (total cholesterol, LDL-C, HDL-C, hs-CRP, creatine and plasma glucose). BMI: body mass index; CRP: C-reactive protein; DBP: diastolic blood pressure; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SOD: superoxide dismutase.
SOD levels and hypertension has not been fully elucidated. The occurrence of diastolic hypertension is related to high sympathetic tension, increased excitability of the RAAS and increased peripheral vascular resistance. In this study, we found that the risk of diastolic hypertension decreased with increasing serum SOD levels up to 58 IU/mL. This may be because SOD protects against oxidative stress, which may reduce diastolic blood pressure by antagonizing RAAS. When the concentration of serum SOD is greater than 58 IU/mL, the effect of SOD antioxidant stress may reach saturation, and the increase in SOD is not related to DBP. A previous study found that the occurrence of isolated diastolic hypertension is closely related to BMI, but in our study, we observed no significant effect modifiers between serum SOD and diastolic hypertension after the stratified analysis by BMI. This difference may be caused by the following reasons: first, the inclusion of different groups of people, as our study included Chinese elderly people over 65 years old and the Framingham Heart Study included people aged 28 to 62. Second, 84.7% of the participants included in our study were people with BMI < 25 kg/m², and the number of people who were overweight was relatively small. Systolic hypertension is usually caused by decreased arterial system elasticity due to increased calcium and collagen deposition on the arterial wall. The effect of SOD is not directly related to the above systolic hypertension mechanisms, which may explain our results that there was no relationship between serum SOD levels and the risk of systolic hypertension. Our findings suggest that increasing the concentration of serum SOD to a certain extent can reduce the risk of diastolic hypertension. A meta-analysis indicated that tempol, a SOD mimic, reduced BP and showed that antioxidant capacity played an important role in prevention after inducing hypertension in various animal models of hypertension. Further research is needed to identify drugs that can safely and effectively increase the level of human serum SOD for the treatment of hypertension.

Our study has some obvious strengths. First, our study results were from an elderly population of CLHLS, which is a prospective, longitudinal, community-based study. This is the first national cohort with an elderly Chinese population and has high-quality data, including demographic and socioeconomic characteristics, social and behavioral risk factors and enough biochemical indexes, with a multistage cluster sampling approach. Second, in this community-based cross-sectional study, for the first time, we found a nonlinear and L-shaped relationship between serum SOD levels and the risk of diastolic hypertension after adjusting for important identified confounders, and the inflection point for the curve was found to be a serum SOD level of 58 IU/mL. Third, enough confounding factors, including demographic characteristics, social and behavioral risk factors and biochemical indexes, were adjusted by correction analysis, which ensures the accuracy and reliability of our results.

This study also has some notable limitations. First, our data only contained the concentration of SOD in serum without SOD activity, which cannot reflect the role of SOD in a more comprehensive way. Second, the data did not distinguish between essential hypertension and secondary hypertension, and it was not possible to determine the relationship between serum SOD levels and these two types of hypertension. Third, the results of our study are only applicable to elderly individuals in China, and the effect of serum SOD levels on BP may be different between young individuals and elderly individuals. Fourth, all the blood tests in this study were only measured once at the same time (2011–2012). The time courses of SOD levels were not measured. Since there was no information about the long-term change in SOD levels, it may lead to inaccurate SOD levels, which may further bias our analysis results. Last, although more than 9,000 people were included in the CLHLS study and more than 2,000 people participated in blood biochemical testing, 1,630 people were eventually included in our study because approximately 800 people were excluded due to lack of important variables. In addition, our study did not address some potential confounding issues that may be related to racial group differences, leading to some bias in the results.

In summary, our results indicated a L-shaped relationship between serum SOD levels and DBP or the risk of diastolic hypertension and found that the inflection point for the curve was a serum SOD level.
of 58 IU/mL. When the serum SOD level is lower than 58 IU/ml, the risk of diastolic hypertension decreases with increasing serum SOD levels and the risk does not decrease when SOD level is higher than 58 IU/mL. Our study suggests that increasing the level of serum SOD to a certain range to increase antioxidant stress is beneficial for the treatment of diastolic hypertension.

COMPETING INTERESTS
None.

RESEARCH FUNDING
This work was supported by grants from the National Natural Science Foundation of China (NSFC 81860070 and 82070350), JiangXi Province Science Foundation for Distinguished Young Scholar (20202ACBL216001) and Jiangxi Province’s Main Discipline Academic and Technical Leader Training Program-Leading Talent Project (20204BCJ22029).

REFERENCES
[1] Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012–2015. Circulation 2018; 137: 2344–2356.
[2] Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2019; 394: 1145–1158.
[3] Gu D, Gupta A, Munter P, et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the International Collaborative Study of Cardiovascular Disease in Asia (InterAsia). Circulation 2005; 112: 658–665.
[4] Li Y, Feng X, Zhang M, et al. Clustering of cardiovascular behavioral risk factors and blood pressure among people diagnosed with hypertension: a nationally representative survey in China. Sci Rep 2016; 6: 27627.
[5] Hayashi K, Naiki T. Adaptation and remodeling of vascular wall; biomechanical response to hypertension. J Mech Behav Biomed Mater 2009; 2: 3–19.
[6] Marek-Trzonkowska N, Kwieczynska A, Reiwer-Gostomska M, et al. Arterial hypertension is characterized by imbalance of pro-angiogenic versus anti-angiogenic factors. PLoS One 2015; 10: e126190.
[7] Fang H, Chen W, Gao Y, et al. Molecular mechanisms associated with Angiotensin-converting enzyme-inhibitory peptide activity on vascular extracellular matrix remodeling. Cardiology 2014; 127: 247–255.
[8] Lee S J, Baek SE, Jang MA, et al. Osteopontin plays a key role in vascular smooth muscle cell proliferation via EGFR-mediated activation of AP-1 and C/EBPbeta pathways. Pharmacol Res 2016; 108: 1–8.
[9] McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 1969; 244: 6049–6055.
[10] Kitiyakara C, Chabrazhivili T, Chen Y, et al. Salt intake, oxidative stress, and renal expression of NADPH oxidase and superoxide dismutase. J Am Soc Nephrol 2003; 14: 2775–2782.
[11] Welch WJ, Chabrazhivili T, Solis G, et al. Role of extracellular superoxide dismutase in the mouse angiotensin slow pressor response. Hypertension 2006; 48: 934–941.
[12] Simic D, Perunovic J, Lasica R, et al. [Plasma and red blood cell superoxide dismutase activity in patients with different stages of essential hypertension]. Med Arh 2005; 59: 156–159. [Article in Bosnian].
[13] Jung O, Marklund SL, Geiger H, et al. Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ Res 2003; 93: 622–629.
[14] Zeng Y, Pang Q, Heseketh T, et al. Survival, disabilities in activities of daily living, and physical and cognitive functioning among the oldest-old in China: a cohort study. Lancet 2017; 389: 1619–1629.
[15] Programs and Partners-Duke Aging Center[EB/OL]. [2021/5/23]. https://sites.duke.edu/centerforaging/programs/ (access on June 10, 2021).
[16] Zeng Y, Vaupel JW, Xiao Z, et al. Sociodemographic and health profiles of the oldest old in China. Population and Development Review, 2002, 28.
[17] Quille J. COX-2 and angiotensin II-induced hypertension and oxidative stress. Am J Hypertens 2011; 24: 1188.
[18] Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29–38.
[19] Lob HE, Marvar PJ, Guzik T J, et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 2010; 55: 277–283,6p-283p.
[20] Gongora MC, Qin Z, Laude K, et al. Role of extracellular superoxide dismutase in hypertension. Hypertension 2006; 48: 473–481.
[21] Lob HE, Vinh A, Li L, et al. Role of vascular extracellular superoxide dismutase in hypertension. Hypertension 2011; 58: 232–239.
[22] Simic D V, Mimic-Oka J, Pjesa-Ercegovac M, et al. Byproducts of oxidative protein damage and antioxidant enzyme activities in plasma of patients with different degrees of essential hypertension. J Hum Hypertens 2006; 20: 149–155.
[23] Xing F, Dong Y, Tao J, et al. [Impact of isolated diastolic hypertension on new-onset cardiovascular and cerebrovascular diseases]. Zhonghua Liu Xing Bing Xue Za Zhi 2014; 35: 956–960. [Article in Chinese].
[24] Franklin S S, Pio J R, Wong N D, et al. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111: 1121–1127.
[25] Alghatrif M, Lakatta E G. The conundrum of arterial
stiffness, elevated blood pressure, and aging. *Curr Hypertens Rep* 2015; 17: 12.

[26] Dornas W C, Silva M, Tavares R, *et al.* Efficacy of the superoxide dismutase mimetic tempol in animal hypertension models: a meta-analysis. *J Hypertens* 2015; 33: 14–23.

Please cite this article as: HUANG Y, LAI W, CHEN H, LIU QF, LI JX, HU JZ. The L-shaped association between superoxide dismutase levels and blood pressure in older Chinese adults: community-based, cross-sectional study. *J Geriatr Cardiol* 2022; 19(1): 71–82. DOI: 10.11909/j.issn.1671-5411.2022.01.002